Abstract
Brain-derived neurotrophic factor (BDNF) is a growth factor implicated in neuronal survival. Studies have reported altered BDNF serum concentrations in patients with Alzheimer’s disease (AD). However, these studies have been inconsistent. Few studies have investigated BDNF concentrations across multiple neurodegenerative diseases, and no studies have investigated BDNF concentrations in patients with frontotemporal dementia. To examine BDNF concentrations in different neurodegenerative diseases, we measured serum concentrations of BDNF using enzyme-linked immunoassay in subjects with behavioral–variant frontotemporal dementia (bvFTD, n=20), semantic dementia (SemD, n=16), AD (n=34), and mild cognitive impairment (MCI, n=30), as well as healthy older subjects (HS, n=38). BDNF serum concentrations were compared across diagnoses and correlated with cognitive tests and patterns of brain atrophy using voxelbased morphometry. We found small negative correlations between BDNF serum concentrations and some of the cognitive tests assessing learning, information processing speed and cognitive control in complex situations, however, BDNF did not predict disease group membership despite adequate power. These findings suggest that BDNF serum concentration may not be a reliable diagnostic biomarker to distinguish among neurodegenerative diseases.
Keywords: Alzheimer’s disease, BDNF, frontotemporal dementia, mild cognitive impairment, neurotrophin, VBM, BDNF serum concentrations.
Current Alzheimer Research
Title:BDNF Serum Concentrations Show No Relationship with Diagnostic Group or Medication Status in Neurodegenerative Disease
Volume: 9 Issue: 7
Author(s): Josh D. Woolley, Eric V. Strobl, Wendy B. Shelly, Anna M. Karydas, R. N. Robin Ketelle, Owen M. Wolkowitz, Bruce L. Miller and Katherine P. Rankin
Affiliation:
Keywords: Alzheimer’s disease, BDNF, frontotemporal dementia, mild cognitive impairment, neurotrophin, VBM, BDNF serum concentrations.
Abstract: Brain-derived neurotrophic factor (BDNF) is a growth factor implicated in neuronal survival. Studies have reported altered BDNF serum concentrations in patients with Alzheimer’s disease (AD). However, these studies have been inconsistent. Few studies have investigated BDNF concentrations across multiple neurodegenerative diseases, and no studies have investigated BDNF concentrations in patients with frontotemporal dementia. To examine BDNF concentrations in different neurodegenerative diseases, we measured serum concentrations of BDNF using enzyme-linked immunoassay in subjects with behavioral–variant frontotemporal dementia (bvFTD, n=20), semantic dementia (SemD, n=16), AD (n=34), and mild cognitive impairment (MCI, n=30), as well as healthy older subjects (HS, n=38). BDNF serum concentrations were compared across diagnoses and correlated with cognitive tests and patterns of brain atrophy using voxelbased morphometry. We found small negative correlations between BDNF serum concentrations and some of the cognitive tests assessing learning, information processing speed and cognitive control in complex situations, however, BDNF did not predict disease group membership despite adequate power. These findings suggest that BDNF serum concentration may not be a reliable diagnostic biomarker to distinguish among neurodegenerative diseases.
Export Options
About this article
Cite this article as:
D. Woolley Josh, V. Strobl Eric, B. Shelly Wendy, M. Karydas Anna, N. Robin Ketelle R., M. Wolkowitz Owen, L. Miller Bruce and P. Rankin Katherine, BDNF Serum Concentrations Show No Relationship with Diagnostic Group or Medication Status in Neurodegenerative Disease, Current Alzheimer Research 2012; 9 (7) . https://dx.doi.org/10.2174/156720512802455395
DOI https://dx.doi.org/10.2174/156720512802455395 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Proteomic Analysis of Alzheimers Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects
Current Alzheimer Research Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients
Current Pharmaceutical Biotechnology Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Clinical Applications of Transcranial Doppler Sonography
Reviews on Recent Clinical Trials The Role of Microbial Agents in the Etiology of Schizophrenia: An Infectious Hypothesis for Psychosis?
Current Immunology Reviews (Discontinued) Clinical Presentation, Treatment Outcome and Survival Among the HIV Infected Children with Culture Confirmed Tuberculosis
Current HIV Research An Unusual Case of Reversible Empty Sella
Endocrine, Metabolic & Immune Disorders - Drug Targets Social Markers of Mild Cognitive Impairment: Proportion of Word Counts in Free Conversational Speech
Current Alzheimer Research Diagnosis and Prognosis of Fetal Cardiomyopathies: A Review
Current Pharmaceutical Design Template Dependent Human DNA Polymerases
Current Topics in Medicinal Chemistry Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research Fork Head Transcription Factors
Current Genomics Nanoparticles as Novel Carrier for Brain Delivery: A Review
Current Pharmaceutical Design